Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-19T12:25:13.260Z Has data issue: false hasContentIssue false
  • English
  • Français

P01-29 - Depression in Parkinson's Disease- Searching for the most Potent Antidepressant

Published online by Cambridge University Press:  17 April 2020

G. Djokic ,
N. Zivkovic ,
D. Pavicevic  and
D. Lazic
G. Djokic
Affiliation:
Consultative Neurology, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
N. Zivkovic
Affiliation:
Urgent Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
D. Pavicevic
Affiliation:
Department M, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia
D. Lazic
Affiliation:
Urgent Psychiatry, Institute for Neuropsychiatry Laza Lazarevic, Belgrade, Serbia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Depression occures in 28- 60% of patients with PD. There is little evidence of the efficacy and safety of antidepressant therapies in Parkinson's disease. This interventive, paralel, RTC, safety/efficiency study included 339 patients aged 36-90, with ICD10/DSMIV criteria for PD and depression. Purpose of the study was to estimate depression, quality of life, and severity od PD symtoms after 3 months of antidepressant therapy.

Methods

We have randomly divide patients into control group(N=45) without antidepressants, and experimental groups in accordance with applied antidepressants: clomipramine(N=48), fluoxetine (N=49), sertraline (N=51), escitalopram (N=49), mirtazepine (N=45), and tianeptine (N=52). We have used HAMD for estimation of depression, QOL scale for quality of life, and UPDRS subscales I(behaviour and mood) and II(daily activities) for PD symptoms at pretrial, and after 3 months scores in all groups. Data were processed with SPSS for Windows.

Results

There is no statistical significance in pretrial scores between groups. After 3 months there is: significant increase in control and significant discrease(p=0.000) of HAMD scores in all experimental groups, in favour of antidepressant with higher mediana(escitalopram 9; sertralin 8; tianeptin 6;clompramin 3; mirtazapin 3;fluoxetine 1; control -2); significant increase of QOL scores in favour of antidepressant with higher mediana(escitalopram 1.24; sertraline 1.12; tianeptine 0.65; clomipramine 0.40; mirtazapine 0.27; fluoxetine 0.27), and significant difference in UPDRS II pretrial and after 3 months subscores(p=0.016), in favour of escitalopram.

Conclusion

All tested antidepressant are efficient in reducing HAMD score, but only escitalopram,sertraline,and tianeptine improved HAMD, QOL, UPDRS I, and II scores without side effects.

Type
Affective disorders / Unipolar depression / Bipolar disorder
Information
European Psychiatry , Volume 25 , Issue S1: 18th European Congress of Psychiatry. February 27, March 2, 2010 - Munich, Germany , 2010 , 25-E248
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.